Literature DB >> 8977809

[Prevalence and role of anticardiolipin antibodies in Crohn disease].

I Lonjon1, L Beaugerie, A Deschamps, C Barthet, F Carbonnel, Y Ngô, J Cosnes, N Abuaf, J P Gendre.   

Abstract

OBJECTIVES: Anticardiolipin antibodies belong to the group of antiphospholid antibodies, and may be seen in association with endothelial damage and recurrent vascular thrombosis. The aim of our study was to determine in patients with Crohn's disease the frequency of anticardiolipin antibodies, and to correlate their presence with clinical activity and treatment of the disease.
METHODS: One hundred and thirty-eight sera from patients with Crohn's disease and 118 from age-matched controls were tested for IgG anticardiolipin antibodies. In the Crohn's disease group, we determined whether the patients had a past history of vascular thrombosis, a clinically active intestinal disease, or a current immunosuppressive therapy (steroids or azathioprine).
RESULTS: Anticardiolipin antibodies were found significantly more often in patients with Crohn's disease than in controls: 11.0% versus 2.5%, P < 0.02. Three patients with Crohn's disease had a past history of vascular thrombosis, but none of them had anticardiolipin antibodies. The presence of anticardiolipin antibodies was not correlated with the fact that patients had a clinically active disease (P = 0.77), or a current immunosuppressive therapy at the time of the serological test (P = 0.95).
CONCLUSIONS: There is a significantly high prevalence of patients with anticardiolipin antibodies during Crohn's disease. The positivity of the test does not seem to be correlated to the existence of a past history of vascular thrombosis, nor to the clinical activity of the disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8977809

Source DB:  PubMed          Journal:  Gastroenterol Clin Biol        ISSN: 0399-8320


  2 in total

1.  Prevalence, significance and predictive value of antiphospholipid antibodies in Crohn's disease.

Authors:  Nora Sipeki; Laszlo Davida; Eszter Palyu; Istvan Altorjay; Jolan Harsfalvi; Peter Antal Szalmas; Zoltan Szabo; Gabor Veres; Zakera Shums; Gary L Norman; Peter L Lakatos; Maria Papp
Journal:  World J Gastroenterol       Date:  2015-06-14       Impact factor: 5.742

2.  Anti-cardiolipin and anti-beta2-glycoprotein I antibodies in patients with inflammatory bowel disease.

Authors:  I E Koutroubakis; E Petinaki; E Anagnostopoulou; H Kritikos; I A Mouzas; E A Kouroumalis; O N Manousos
Journal:  Dig Dis Sci       Date:  1998-11       Impact factor: 3.199

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.